“Is it time to test embryos for common diseases?” — MedicalXpress.com


“A Silicon Valley company has designed a technique to decipher the genetic code of a tiny embryo and calculate its future risk of cancer, diabetes and 10 other common diseases—presaging a day when parents could select children with a greater chance of living a healthier life.”

Read full article at MedicalXpress.com

Contact Us

We are happy to answer any questions. Contact us at info@myome.com with any questions or to keep apprised of any development, provide your name and email information.

footer logo
linkdin

© 2023 MyOme.com

MyOme is not responsible for the content or accuracy of third-party websites

The MyOme Personal Genome Report was developed, and its performance characteristics were determined, by MyOme, Inc., a clinical laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity clinical laboratory testing. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary for laboratory-developed tests.